Composition: 1 ml contains:

active ingredients: semisynthetic paclitaxel – 6 mg.

Therapeutic indications

  • Ovarian Cancer

The 1st line therapy (in combination with cisplatin) in patients with advanced metastatic or residual tumor (more than 1 cm) after laparotomy and the 2nd line therapy in patients with advanced metastatic ovarian cancer after unsuccessful standard therapy.

  • Breast cancer

Adjuvant therapy in patients with lymph nodes metastasis after standard combination therapy, the 1st line therapy in metastatic cancer and the disease aggravation after adjuvant therapy with anthracyclines, the 2nd line therapy with the disease aggravation after combination chemotherapy with anthracycline antitumor antibiotics.

  • Non-small cell lung cancer

The 1st line therapy in combination with cisplatin or monotherapy in patients who haven’t been planned for surgery and/or radiation therapy with the chance to be cured.

  • Kaposi's sarcoma in AIDS patients: the 2nd line therapy.

АТС code


Pharmaceutical form

concentrate for preparing solution for infusion 100 mg/16,7 ml and 30 mg/5 ml

Storage conditions

Store in protected from light place, at the temperature below 25ºС.